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Background:  The purpose of this study was to investigate a dosage of remifentanil for attenuating cardiovascular 
changes during anesthetic induction in pediatric anesthesia.
Methods:  We examined the effect of remifentanil on the cardiovascular responses to intubation in 90 children 
ASA 1 patients, aged 4-15 years, randomly allocated to receive 1.0 ug/kg remifentanil as a bolus (R 1), or 1.5 ug/
kg remifentanil (R 1.5), or 2.0 ug/kg remifentanil (R 2).  Before induction, IV midazolam 0.05 mg/kg was given 
for sedation.  After glycoppylorate 5 ug/kg, thiopental 4.0 mg/kg was injected within 10 seconds and followed by 
remifentanil.  Following check the unconsciousness, patients were received rocuronium 0.6 mg/kg and tracheal 
intubation were performed 90s later, and anesthesia was maintained with 2% sevoflurane in air/oxygen.  Systolic 
arterial pressure (SAP), mean arterial pressure (MAP) and heart rate (HR) were measured at before induction of 
anesthesia (B), before, just after and at 1, and 3 minutes after tracheal intubation.
Results:  SAP and HR were increased than B values in the three groups just after intubation (P < 0.05).  The 
percentage increases of SAP and HR were 30% and 30% of B values, respectively, in R 1; 19% and 24% in R 1.5; 10% 
and 22% in R 2. There were significant differences between R 2 group and other two groups in SAP and HR (P < 0.05).
Conclusions:  In pediatric anesthesia, a bolus injection of 2 ug/kg remifentanil (R 2) was a dosage to attenuate the 
cardiovascular responses after intubation in pediatric patients.  (Korean J Anesthesiol 2010; 59: 167-172)
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Introduction
    When performing adult general anesthesia, endotracheal 
intubation (ETI) using a laryngoscope stimulates the 
sympathetic nervous system and it raises the blood pressure, 
the heart rate and the, catecholamine concentration in the 
blood [1,2]. Raising the blood pressure and heart rate increases 
the danger of myocardial ischemia, left ventricular failure, 
arrhythmia, and cerebral hemorrhage [3-5]. Likewise in pediatric 
anesthesia, endotracheal intubation using a laryngoscope 
temporarily raises the catecholamine concentration and 
greatly increases the systolic blood pressure and heart rate 
[6]. Such temporary increases in the cardiovascular responses 
in the patients with pulmonary hypertension, and cerebral 
vascular malformation, and the increased intracranial 
pressure poses a potential threat; therefore it is important to 
prevent the cardiovascular changes due to ETI [7,8]. The use 
of opioids can decrease such cardiovascular responses [9-11]. 
Compared with the currently marketed fentanyl congeners, the 
pharmacokinetic profile of remifentanil is unique. Remifentanil 
has an ester-bond and this is quickly hydrolyzed by nonspecific 
esterase in the plasma and the organs. Its maximum effect 
kicks in within 30-90 sec; its context-sensitive half life is less 
than 5 minutes. So regardless of the infusion time, when the 
remifentanil infusion is stopped, its effect quickly ceases and 
the emergence from remifentanil becomes predictable [12]. 
Therefore, opioids of an appropriate dose are recommended 
in surgeries that require quick recoveries. Remifentanil’s 
terminal elimination half life in pediatric patients is 3.4-5.7 
minutes, which is very short and similar to the case of adults 
[13]. Therefore, remifentanil is considered to be effective in 
preventing the cardiovascular responses to short-term harmful 
stimulations such as ETI. There have been many reports on 
what the optimum dose of remifentanil is in adults who are 
undergoing ETI [14]. But in Korea, not many studies have been 
performed on the optimum dose of remifentanil in pediatric 
patients. Therefore, this research attempted to find the optimum 
dose that would minimize the cardiovascular changes due to 
ETI in pediatric patients.
Materials and Methods
    This research first received the approval of the hospital’s ethics 
committee. Then the guardians of the patients had the purpose 
and methodology of the study explained, and their informed 
consent was obtained.
    Ninety ASA class I pediatric patients between the ages 4-15 
and who were undergoing elective surgery under general 
anesthesia were chosen. Patients were excluded if they 
had a past history of cardiovascular disease, upper airway 
deformation, and if ETI had to be attempted twice or more 
because of difficult intubation. The patients were allocated to 
one of three groups in a randomized manner. Each group was 
respectively given remifentanil 1 ug/kg (Group R1; N = 30), 1.5 
ug/kg (Group R1.5; N = 30), and 2 ug/kg (Group R2; N = 30).
    When the patients arrived into the operating room, 
midazolam 0.05 mg/kg was intravenously administered. After 
the patients were stabilized on the operative table, a noninvasive 
blood pressure monitor (MP40, Philips, Germany), the ECG, 
and a pulse oximetry sensor were attached. Glycopyrrolate 
5 ug/kg was intravenously administered as premedication. 
For anesthetic induction, thiopental sodium 4 mg/kg was 
intravenously administered. When the patient did not respond 
to oral commands and there was no eyelash reflex, remifentanil 
of the amount for the respective group was diluted in normal 
saline 5 ml and this was administered by intravenous bolus 
injection over 10 seconds. This was quickly followed by the 
administration of rocuronium 0.6 mg/kg. Ninety sec afterwards, 
ETI was performed using a curved laryngoscope (Macintosh, 
Heine, Germany). 
    Intubation was performed by a skilled anesthesiologist with 
3 yrs of experience. Intubation was easy in most cases. After 
intubation, anesthesia was maintained by sevoflurane 2 vol%, 
air 2.5 L/min and, O2 1.5 L/min. The ventilator settings were 
adjusted to maintain the end-expired carbon dioxide at 35-
40 mmHg. After intubation, the blood pressure and heart rate 
were measured without fixing the tube or changing the body 
position of the patient for the patients whose blood pressure 
and heart rate would increase. The systolic blood pressure, mean 
blood pressure, and heart rate were measured before anesthetic 
induction (B), before intubation (BI), just after ETI (P 0), 1 minute 
after ETI (P 1), and 3 minutes after ETI (P 3). The rate of occurrence 
of coughing after remifentanil administration was also recorded. 
    All the data is presented as means ± standard deviations. The 
results were processed on SPSS (version 17.0). The analysis 
of the gender of the 3 groups was performed using the chi-
square test. The age, height, and weight were analyzed by one-
way ANOVA. The comparative analyses of the blood pressure 
and heart rates among the groups were done using one-way 
ANOVA. A post-hoc analysis was performed using Duncan’s 
test. The changes of the blood pressure and heart rate within 
the groups that were measured at different times were analyzed 
using repeated measures of ANOVA. P values < 0.05 were 
considered to be statistically significant. 
Results
    There were no significant differences between the 3 groups 
for gender, age, height, or weight. Neither were there significant 
differences in the systolic blood pressure, mean blood pressure, 169 www.ekja.org
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and heart rate before anesthetic induction (Table 1).
    The systolic blood pressure in all the 3 groups rose more 
than the baseline value (B) just after ETI (P < 0.05) (Fig. 1). The 
systolic blood pressure just after ETI in Group R1 increased 
30% (141.4 ± 17.9 mmHg) more than the baseline value, and 
it increased 19% (128.9 ± 14.8 mmHg) more than the baseline 
value in Group R1.5, and 10% (117.8 ± 13.0 mmHg) more than 
the baseline value in Group R2. In Group R2, the blood pressure 
just after ETI was significantly lower (P < 0.05) compared to that 
of the other 2 groups. The systolic blood pressure eventually 
dropped in all 3 groups at 1 min post-ETI. At 3 min post ETI, 
the systolic blood pressure in Group R1 was 5% greater than 
the baseline value. In Groups R1.5 and R2, the systolic blood 
pressure was 5% and 10% lower than the baseline value, 
respectively. There was no significant difference between Group 
R1.5 and Group R2. 
    The mean blood pressure in all 3 groups rose just after 
intubation (P < 0.05) (Fig. 2). The mean blood pressure just after 
ETI in Group R1 (106.5 ± 18.4 mmHg) rose 44% more than the 
baseline value, and it rose by 20% (86.5 ± 12.4 mmHg), and 27% 
(94.2 ± 17.9 mmHg) more than the baseline value in Group R1 
and R1.5, respectively (P < 0.05). The mean blood pressure just 
after ETI in Group R2 and Group R1.5 was significantly lower 
than that in Group R1 (P < 0.05). One minute post ETI, the mean 
blood pressure eventually dropped in all 3 groups. In Groups 
R1 and R1.5, the mean blood pressure was no different from the 
baseline rate, but in Group R2, it was 11% lower (P < 0.05). 
    The heart rate in all three groups rose the most just after 
ETI compared to the baseline value and then it eventually 
decreased (Fig. 3). Just after ETI, Group R2 displayed a 22% rise 
Table 1. Demographic Data
Group R1
(n = 30)
Group R1.5
(n = 30)
Group R2
(n = 30)
Gender (M/F)
Age (yr)
Weight (kg)
Height (cm)
Baseline blood pressure
  SAP (mmHg) 
  MAP (mmHg) 
Baseline HR (bpm)
14/16
7.6 ± 3.2
29.6 ± 12.3
126.4 ± 19.4
108.4 ± 11.6
73.9 ± 11.7
96.3 ± 17.0
14/16
8.5 ± 3.6
32.3 ± 12.3
132.8 ± 21.9
107.9 ± 11.7
73.6 ± 9.4
93.8 ± 14.2
18/12
7.9 ± 2.9
29.8 ± 10.4
124.0 ± 27.0
107.3 ± 10.0
71.9 ± 8.4
92.1 ± 11.4
Value are means ± SDs. R1: remifentanil 1.0 ug/kg, R1.5: remifentanil 
1.5 ug/kg, R2: remifentanil 2 ug/kg. SAP: systolic arterial pressure, 
MAP: mean arterial pressure, HR: heart rate. There were no signi-
ficant differences among the three groups.
Fig. 1. Changes in the systolic arterial pressure (SAP). Group R1: 
remifentanil 1 ug/kg, Group R1.5: remifentanil 1.5 ug/kg, Group R2: 
remifentanil 2 ug/kg, B: baseline, BI: before intubation, P0: just after 
intubation, P1 and, P3: 1 and, 3 minutes after intubation. *P < 0.05 
compared with Baseline, 
†P < 0.05 compared with Group R1, 
‡P < 
0.05 compared with Group R1.5.
Fig. 2. Changes in the mean arterial pressure (MAP). Group R1: 
remifentanil 1 ug/kg,  Group R1.5: remifentanil 1.5 ug/kg, Group R2: 
remifentanil 2 ug/kg, B: baseline, BI: before intubation, P0: just after 
intubation, P1 and, P3: 1 and, 3 minutes after intubation. *P < 0.05 
compared with Baseline, 
†P < 0.05 compared with Group R1, 
‡P < 
0.05 compared with Group R1.5.
Fig. 3. Changes in heart rate (HR). Group R1: remifentanil 1 ug/kg, 
Group R1.5: remifentanil 1.5 ug/kg, Group R2: remifentanil 2 ug/
kg, B: baseline, BI: before intubation, P0: just after intubation, P1 
and, P3: 1 and, 3 minutes after intubation. *P < 0.05 compared with 
Baseline, 
†P < 0.05 compared with Group R1.170 www.ekja.org
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in the heart rate (112.9 ± 14.9 bpm), which was significantly less 
than the 30% rise of Group R1 (125.1 ± 16.1 bpm) (P < 0.05). 
But just after ETI, the heart rates of Group R1.5 (117.3 ± 17.2 
bpm) and Group R1 (125.1 ± 16.1 bpm) were not significantly 
different. Three minutes after ETI, the heart rate was higher than 
the baseline value in all 3 groups, but there was no significant 
difference between them. 
    There was no significant difference in the rates of coughing 
after the bolus administration of remifentanil (Group R1: 53%, 
Group R1.5: 60%, Group R2: 56%). 
Discussion
    The key finding of this study is that for general anesthesia 
using thiopental, remifentanil, and rocuronium for anesthetic 
induction in pediatric patients, remifentanil with the dose 2.0 
ug/kg best suppresses the cardiovascular responses to ETI. 
    Remifentanil’s onset time is rapid and its duration of action 
is short. Therefore, it is effective regardless of the duration time 
of continuous infusion and, it is hydrolyzed at a set pace, so it 
is also the most preferred analgesic or anesthetic for diagnostic 
procedures and surgeries for pediatric patients [15]. Egan et al. 
[16] stated that when the use of strong analgesics over a short 
period is required, bolus IV infusion of remifentanil is safe and 
effective. So, we also chose the bolus administration method 
for remifentanil over the continuous infusion method. ETI was 
performed in this research 90 sec after remifentanil injection 
because remifentanil’s peak pharmacodynamic effect kicks in 1 
to 2 minutes after the injection [17]. 
    Xue et al. [10] stated that the optimum dose of remifentanil 
is 1 or 1.25 ug/kg for blunting the cardiovascular responses 
to ETI when anesthesia is induced in pediatric patients using 
propofol 2.5 mg/kg and vecuronium 0.1 mg/kg. But in this 
study, the optimum dose of remifentanil was found to be 2 
ug/kg. The difference compared to the findings of Xue et al. 
[10] is considered to be from our use of thiopental instead 
of propofol and the use of glycopyrrolate as premedication. 
Propofol 2.5 mg/kg that Xue et al. used is considered to be 
a much greater dose than the thiopental 4 mg/kg we used. 
Compared to thiopental, propofol causes less secretion of 
stress hormones due to anesthetic induction and ETI. It also 
suppresses the effect of catecholamine, which is secreted due 
to the stimulation of the intubation on the cardiovascular 
smooth muscle and so propofol does not greatly raise the blood 
pressure [18,19]. Thiopental 5-6 mg/kg is generally used for 
anesthetic induction. However, in our research, midazolam 0.05 
mg/kg was intravenously administered to calm the pediatric 
patients before anesthetic induction, and so we used thiopental 
4 mg/kg. 
    In the presented research, glycopyrrolate was also administered 
as premedication, which we assume caused the heart rate 
before intubation (BI) to increase in all 3 groups and the systolic 
blood pressure to rise in only Group R1. Xue et al. found that 
with remifentanil 1.25 ug/kg, the systolic blood pressure and 
heart rate just after intubation rose 1% and 8%, respectively. But 
our different findings of 10% and 22% increases in Group R2 
are considered to be due to the presence of glycopyrrolate and 
propofol. 
    The fact that the blood pressure decreases after intubation 
should be considered when choosing the optimum amount of 
remifentanil for suppressing the post-intubation blood pressure 
elevation. In the present research, the blood pressure decreased 
slightly from the baseline value at 3 min post ETI in Group R1.5 
and Group R2 (5% and 10% respectively). But there was no 
significant difference between the two groups. So remifentanil 
at the dose 2.0 ug/kg is considered the appropriate dose for 
greater suppression of the elevated blood pressure elevation 
just after ETI. Also in Xue et al.’s findings, remifentanil 1 ug/
kg and 1.25 ug/kg reduced the systolic blood pressure around 
15% below the baseline value at 5 min after intubation. But 
this is considered to be from the use of propofol because the 
control group, where remifentanil was not used, showed no 
difference in the drop in blood pressure. Cha et al. [20] stated 
that remifentanil 0.5 ug/kg is appropriate to suppress the 
cardiovascular responses to ETI in adults when anesthesia is 
induced by propofol 2 mg/kg or rocuronium 1 mg/kg. Lee et 
al. [21] also reported that remifentanil 1 ug/kg is appropriate 
when anesthesia is induced by sevoflurane 2 vol% and N2O 
50% in adults. McAtamney et al. [22] reported that remifentanil 
1.0 ug/kg is the optimum dose when anesthesia is induced by 
thiopental 5-7 mg/kg and rocuronium 0.75 mg/kg in adults. In 
summary, the optimum dose of remifentanil has been reported 
to be 0.5-1.0 ug/kg, but for children, this study demonstrated 
that the optimum dose is 2 ug/kg, which is a higher dose 
than that for adults. Although it is difficult to make accurate 
comparisons between anesthetic inducers and their dose, it 
is thought that the dose for children does not necessarily have 
to be smaller than that for adults. Ross et al. [13] stated that 
remifentanil’s volume of distribution is pharmacokinetically 
greater for children and, its clearance rate is faster, but there was 
no difference seen in the elimination rate.
    Mark et al. [23] stated that in children where muscle relaxants 
have not been used and propofol 4 mg/kg was used for 
anesthetic induction, remifentanil’s optimum dose is 3.0 ug/
kg. Blair et al. [6] stated that when using propofol 3 mg/kg 
for anesthetic induction in the absence of muscle relaxants, 
remifentanil 2-3 ug/kg will decrease the blood concentration 
of catecholamine, it will not raise the blood pressure and 
heart rate due to ETI, and it will bring about hemodynamic 
stabilization. Klemola and Hiller [24] stated that in the absence 171 www.ekja.org
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of muscle relaxants, propofol 3.5 mg/kg and remifentanil 4 ug/
kg provide the best conditions for intubation. For pediatric 
anesthesia, when intubation is performed without muscle 
relaxants, a greater dose of remifentanil has generally been 
used.
    In this present study, rocuronium 0.6 mg/kg was administered 
for intubation. Most of the surgeries were short like a tonsillec-
tomy, so a greater dose was not needed. Ninety seconds after 
administering rocuronium, ETI were performed uneventfully. 
Eikermann et al. [25] stated that ETI was easy 2 minutes after 
administering rocuronium 0.6 mg/kg in pediatric patients 
where inhalational anesthesia with sevoflurane 8% and nitrous 
oxide 60% was used. 
    Coughing, a side effect of the use of opioids, was found in 
Groups R1, R1.5, and R2 with the respective frequency of 
53%, 60%, and 56%. There was no statistically significant 
difference found among the 3 groups. This may be because 
only the presence/absence of coughing was recorded and 
the frequency was not. There were no other findings such as 
bradycardia. Coughing that occurs during anesthetic induction 
can elevate the intracranial pressure, intraocular pressure, 
and intra-abdominal pressure; in the case of severe coughing, 
immediate intervention is required [26]. Xue et al. [10] reported 
that they did not encounter opioid-related side effect, such 
as bradycardia, coughing or chest rigidity. In our study, 
remifentanil was intravenously administered over 10 seconds. 
But Xue et al. administered it over 30 seconds and there were 
no side effects, which may be due to the small dose (1 or 1.25 
ug/kg). Lin et al. [27] stated that the incidence of coughing 
from fentanyl can be reduced by its slow administration. More 
studies are needed on the relationship of coughing to the dose 
of remifentanil, the method of administration and the infusion 
speed. 
    Whether the appropriate dose for remifentanil is lower when 
the thiopental is increased from 4 mg/kg to 5 mg/kg or when 
propofol is used instead needs to be addressed in another 
study. 
    We know that the greater the amount of bolus infusion of 
remifentanil, the greater the increased blood pressure just 
after intubation is suppressed. However, when choosing 
the appropriate dose, one must also consider that the blood 
pressure drops to a greater degree after 3 minute post ETI. 
    In conclusion, the bolus injection of remifentanil 2 ug/kg was 
found to be effective to minimize the cardiovascular responses 
when anesthesia is induced in pediatric patients using 
thiopental and rocuronium.
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